SCHEMBL2854775

SCHEMBL2854775

Cc1nc2ccccc2n1C(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.57
ALDH1A1 P00352 7/20 0.57
KDM4E B2RXH2 4/20 0.57
HPGD P15428 3/20 0.57
KMT2A Q03164 2/20 0.57
LMNA P02545 5/20 0.55
TP53 P04637 2/20 0.55
RAB9A P51151 2/20 0.55
MAPT P10636 2/20 0.55
ALPG P10696 1/20 0.55
TSHR P16473 6/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPC1 O15118 1/20 0.54
GLA P06280 1/20 0.54
GAA P10253 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
RPS6KB1 P23443 1/20 0.53
GSK3B P49841 1/20 0.53
ROCK1 Q13464 1/20 0.53
HTT P42858 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6910150 0.88 TSHR (0.53) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL10538765 0.85 LMNA (0.51) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL20683078 0.82 TSHR (0.47) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL18250747 0.82 ALDH1A1 (0.58) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL1980314 0.80 HSD17B10 (0.57) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL2607467 0.79 ALDH1A1 (0.72) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL18250744 0.79 HTT (0.55) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL18250699 0.79 TSHR (0.51) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL1128688 0.78 SMN1; SMN2 (0.60) HSD17B10ALDH1A1KDM4EHPGDKMT2A
SCHEMBL1104440 0.78 HSD17B10 (0.56) HSD17B10ALDH1A1KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378232-B2 Cyclin dependent kinase inhibitors PFIZER INC. (US) 2025-08-05 US disclosed
CN-119707834-A Preparation method of arbeli and intermediate thereof 常州制药厂有限公司 2025-03-28 CN disclosed
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20230200205-A1 Emitting Compound and Organic Light Emitting Device Including the Same LG DISPLAY CO., LTD. (KR) 2023-06-22 US disclosed
US-20230189642-A1 Emitting Compound and Organic Light Emitting Device Including the Same LG DISPLAY CO., LTD. (KR) 2023-06-15 US disclosed
EP-4157847-A1 DRUG-LIKE MOLECULES AND METHODS FOR THE THERAPEUTIC TARGETING OF VIRAL RNA STRUCTURES University of Washington (US) 2023-04-05 EP disclosed
US-20220089580-A1 CYCLIN DEPENDENT KINASE INHIBITORS PFIZER INC. (US) 2022-03-24 US disclosed
US-20220000883-A1 PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO EMORY UNIVERSITY 2022-01-06 US disclosed
US-11203613-B2 Peptidomimetic proteasome inhibitors CORNELL UNIVERSITY 2021-12-21 US disclosed
US-20210284805-A1 DESIGN OF LIGAND ATTACHMENT CHEMISTRY FOR HIGH CONDUCTIVITY POLYMER ELECTROLYTES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-09-16 US disclosed
US-20090288707-A1 Novel compounds for electronic material and organic electronic device using the same GRACEL DISPLAY INC. (KR) 2009-11-26 US disclosed
US-20090273277-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-11-05 US disclosed
US-7589204-B2 Indane compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-09-15 US disclosed
US-20090187021-A1 INDANE COMPOUNDS AS CCR5 ANTAGONISTS YOUNGMAN MICHAEL 2009-07-23 US disclosed
US-7531661-B2 Indane compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-05-12 US disclosed
US-7531661-B2 Indane compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-05-12 US disclosed
EP-2040666-A2 BENZIMIDAZOLES AS COOLING COMPOUNDS Givaudan SA (CH) 2009-04-01 EP disclosed
WO-2008006236-A2 BENZIMIDAZOLES AS COOLING COMPOUNDS GIVAUDAN SA (CH) 2008-01-17 WO disclosed
US-20070015773-A1 Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders AMGEN INC. 2007-01-18 US disclosed
US-6875765-B2 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY (US) 2005-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000883-A1 PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO PTGER2, PTGES2, PTGER1 HSD17B10 3141/4885ALDH1A1 1095/4885KDM4E 3087/4885
US-20090273277-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, ORMDL3, CHRM2 HSD17B10 1775/4885ALDH1A1 818/4885KDM4E 3872/4885
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF MDM2, CUL1, PSMG3 HSD17B10 2131/4885ALDH1A1 3843/4885KDM4E 935/4885
US-11203613-B2 Peptidomimetic proteasome inhibitors PSMB1, PSMB3, PSMB11 HSD17B10 4401/4885ALDH1A1 4639/4885KDM4E 1197/4885
US-12378232-B2 Cyclin dependent kinase inhibitors CCNY, CCNI, CCNK HSD17B10 4271/4885ALDH1A1 4211/4885KDM4E 715/4885
US-20070015773-A1 Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders CCR1, MSR1, CCR2 HSD17B10 2108/4885ALDH1A1 742/4885KDM4E 3102/4885
US-20220089580-A1 CYCLIN DEPENDENT KINASE INHIBITORS CCNY, CCNI, CCNK HSD17B10 4271/4885ALDH1A1 4211/4885KDM4E 715/4885
US-20090187021-A1 INDANE COMPOUNDS AS CCR5 ANTAGONISTS CCR5, CCL5, IDO1 HSD17B10 2373/4885ALDH1A1 2472/4885KDM4E 4383/4885
US-20090288707-A1 Novel compounds for electronic material and organic electronic device using the same OCIAD1, OCIAD2, ORMDL3 HSD17B10 2120/4885ALDH1A1 498/4885KDM4E 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.